Fétique-Will Anne-Catherine, Chevalley Thierry, Rizzoli René
Service de psychiatrie générale, Département de santé mentale et de psychiatrie, HUG, 121I Genève 14.
Rev Med Suisse. 2011 Jun 15;7(299):1299-304.
Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI.
选择性5-羟色胺再摄取抑制剂（SSRI）是抑郁症的一线治疗药物。多项研究表明，使用治疗剂量的SSRI与骨矿物质密度（BMD）降低及骨折风险增加有关。SSRI对骨组织的作用机制尚未完全阐明。这些治疗可能与跌倒风险增加有关，并且可能对骨代谢有直接影响。鉴于已有证据表明SSRI与骨质疏松症有关，在等待大规模前瞻性研究的同时，临床医生对接受SSRI治疗的患者风险群体进行骨质流失评估似乎是合理的。
